Tazverik Tablets
Tazverik, developed by Epizyme Inc. and marketed by Ipsen, is an FDA-approved oral monotherapy indicated for adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation. The treatment is specifically for those who have received at least two prior systemic therapies and have no satisfactory alternative options available.
The approval of Tazverik is based on accelerated approval criteria, focusing on overall response rates and duration of response, with continued approval contingent upon further clinical trials to verify its benefits. Tazverik is included in the NCCN Clinical Practice Guidelines for B-cell Lymphomas, highlighting its significance as a treatment option for eligible patients.
Generated from the website
Also at this address
You might also like
Partial Data by Infogroup (c) 2024. All rights reserved.
